ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Impaired serological response to COVID-19 vaccination following anticancer therapy: A systematic review and meta-analysis

Tang, Kefu*; Wei, Zhiying; Wu, Xi*复旦大学; 上海交通大学
Journal of Medical Virology2022-10DOI: 10.1002/jmv.27956
10被引6阅读
引用收藏
分享

摘要

Owing to the high coronavirus disease 2019 (COVID-19)-related morbidity and fatality rate among patients with cancer, the introduction of COVID-19 vaccines is of profound significance in this fragile population. Accumulating data suggested that oncologic patients, especially those with anticancer therapy have an impaired immune response to COVID-19 vaccination. However, the exact effect of anticancer treatments on postvaccination response has not been elucidated yet. We, therefore, conducted a meta-analysis to evaluate the impact of treatments on response to COVID-19 vaccination in patients with cancer. A total of 39 studies were finally included comprising 11 075 oncologic patients. Overall, we found the humoral response was significantly decreased in patients undergoing anticancer treatments (odds ratio [OR] = 2.55, 95% confidence interval [CI]: 2.04-3.18) compared with those without active treatment. The seroconversion rates were significantly lower in patients with chemotherapy (OR = 3.04, 95% CI: 2.28-4.05), targeted therapy (OR = 4.72, 95% CI: 3.18-7.01) and steroid usage (OR = 2.19, 95% CI: 1.57-3.07), while there was no significant association between immunotherapy or hormonal therapy and seroconversion after vaccination. Subgroup analyses showed therapies with anti-CD20 antibody (OR = 11.28, 95% CI: 6.40-19.90), B-cell lymphoma 2 inhibitor (OR = 5.76, 95% CI: 3.64-9.10), and Bruton tyrosine kinase inhibitor (OR = 6.86, 95% CI: 4.23-11.15) were significantly correlated with the risk of negative humoral response to vaccination. In conclusion, our results demonstrated that specific oncologic therapies may significantly affect serological response to COVID-19 vaccines in patients with cancer. Thus, an adapted vaccination strategy taking the influence of active treatment into account is in need, and further research on the effect of the third dose of vaccine and the role of postvaccination cellular response in oncologic patients is also needed.

学科与关键词

关键词
cancerCOVID-19 vaccinesserological responsetreatment
相关
加载中…
  • PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness
    Chen, Xiangyu; Lin, Yao; Yue, Shuai; Yang, Yang; Yang, Xiaofan; He, Junjian; Gao, Leiqiong; Li, Zhirong; Hu, Li; Tang, Jianfang; Wang, Yifei; Tian, Qin; Hao, Yaxing; Xu, Lifan; Huang, Qizhao; Cao, Yingjiao*; Ye, Lilin*Vaccine, 2023, 41(34): 4986-4995.
  • Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients
    Wu, Xi; Wang, Lu; Shen, Lu; He, Lin; Tang, Kefu*Journal of Hematology & Oncology, 2022, 15(1): 81.被引 25
  • Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19
    Huang, Yongsheng; Yu, Jing; Li, Dan; He, Kai; Liu, Wenyang; Wang, Lin; Chen, Yeshan*; Xie, Conghua*; Wu, Xiaowei*Scientific Reports, 2021, 11(1): 17381.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Medical Virology
发表日期
2022-10
卷期
第 94 卷, 第 10 期
页码
4860-4868
DOI
10.1002/jmv.27956
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
Research Start-up Fund in Changning Maternity and Infant Health Hospital [2021Y-15]

作者

  • T

    Tang, Kefu (通讯) (第一作者)

  • W

    Wei, Zhiying

    fudan univ

查看全部 3 位作者收起作者
  • W

    Wu, Xi (通讯)

    shanghai jiao tong univ · x

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417